Clinical Trial Update: Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating veliparib with or without mitomycin C in patients with metastatic, unresectable, or recurrent solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Mitomycin-C (mitomycin C)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Solid Neoplasm | Phase 1 | Status: COMPLETED